Every year, the Rare Disease community comes together on the last day of February to raise awareness of rare diseases that affect more than 300 million people worldwide. Rare Disease Day was launched by the European Organisation for Rare Diseases (EURORDIS) and its Council of National Alliances in 2008, and since then, we have made great strides toward the development of therapies for rare diseases.
ICON is a proud member of the US National Organisation for Rare Disorders (NORD) and EURORDIS, and over the past five years, we have conducted more than 730 rare disease studies. This year, ICON’s Centre for Rare Diseases is hosting a series of activities to help raise awareness and generate change for the millions people worldwide living with a rare disease, their families and carers. These events will kick off on Rare Disease Day and include a four-day webinar series of panel discussions later in March.
This year’s Rare Disease Day theme is #ShareYourCOLOURS to highlight the diversity and uniqueness of those living with rare diseases and the rare disease community. As such, our activities are focusing on diversity, equity, inclusion and accessibility within the context of rare disease and rare disease clinical research. To amplify awareness and expand our reach to the widest possible audience, we share a few considerations for making your own virtual events more accessible and inclusive.
Developing an accessible virtual event
On 27-30 March, ICON will host a four-day webinar series exploring accessibility in rare disease clinical research. With multiple interdisciplinary panel discussions of research leaders and community advocates, we will provide insights into the value of accessibility and how sponsors, patient advocates, researchers and regulators can take action.
As the theme of this year’s Rare Disease Day is diversity within rare disease, it’s important to ensure that the activities planned are accessible and inclusive. The challenges around digital and virtual accessibility restrict the ability for those living with disability to engage with information.
Considering what potential barriers participants might face is the first step in removing them. At ICON, as we began the process of developing these accessible virtual events by researching accessibility best-practices for virtual events and assessing where we could make improvements. Beyond desktop research, it is critical to engage the diverse communities directly through discussions with accessibility advocates or other related advocacy groups. The combination of research and direct input from communities allows for a more thoughtful, tailored approach. Through this exercise, we identified the most appropriate accommodations, including the most valuable technical features that will enhance accessibility for our virtual events as well as the importance of language accessibility.
Defining accessibility requirements
After the research and consideration phase, we recommend creating a clear list of accessibility requirements for the event. Based on discussions with experts, panel participants and other internal and external stakeholders, we developed a prioritised list of accessibility requirements based on the parameters of the event, its goals and the communities attending. Defining these requirements helps guide event planning decisions, including selection of the host platform.
For our upcoming virtual events, we considered a wide range of accommodations including:
- Closed captioning in English and other languages
- Screen reader capabilities (for registration page and panels)
- Multiple simultaneous screen viewing (to accommodate an ASL interpreter in the same frame as the speakers)
- Transcription and translation
- Simultaneous audio translation into other languages
- High contrast modes or other visual modifications
While considering accessibility requirements for the virtual event, it is important to weigh the individuals’ experience against the perceived improvement of accessibility. For example, simultaneous audio translation into other languages is one way to improve accessibility for attendees that speak other languages, but it would require guests to go into breakout rooms. Dividing individuals into separate rooms may undermine the goals of collaboration and community building and would prevent them from getting to know the panellists.
Platform selection
When hosting a virtual event, there are numerous platforms available that offer a variety of functionalities, production support and pricing models. It may be difficult to find a platform that accommodates the list of accessibility requirements while also fitting other event planning constraints. A good starting point for this evaluation process is the American Bar Association’s (ABA) Virtual Meetings: Accessibility Checklist & Best Practices. The ABA Accessibility Features of Common Virtual Platforms list illustrates which of the common platforms includes various accessibility features. Each platform has their own built-in accessibility features and plug-in options, but they each have unique constraints as well. After selecting the best-fit platform, discuss best practices with the platform vendor to ensure the accessibility accommodations are fully implemented.
Translations and language accessibility
Language considerations are another key accessibility point. Virtual event platforms may provide ASL or closed captioning accommodations, but not linguistic translations. As a global organisation, we fully comprehend the necessity of providing target-language translations to facilitate accessibility and inclusion for diverse audiences. For our Rare Disease Day virtual events, ICON’s Language Services teams are providing full-service translations for live and post-event services. We are utilising a mix of live ASL translation and post-event transcript translations into multiple target languages – including Spanish, French, Hindi, Mandarin, Portuguese and German – to create accurately subtitled recordings.
Join us and #ShareYourColours
Rare Disease Day aims to raise awareness amongst the general public and key decision-makers about rare diseases and the diversity of individuals affected by them. By creating more accessible and inclusive events, we can collectively reach more people and help generate change for the millions of people worldwide that are living with a rare disease.
Learn more and register today for our interdisciplinary four-day webinar series, ‘Rare disease week 2023: Exploring accessibility in rare disease clinical research’ taking place on 27-30 March.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel